Amicas finalizes Sunquest deal
Amicas finalizes Sunquest dealWeb-based PACS developer Amicas and RIS firm Sunquest Information Systems have formalized their relationship. The two companies, which showed integration work at the 1998 RSNA meeting (PNN 1/99), have wrapped
Amicas finalizes Sunquest deal
Web-based PACS developer Amicas and RIS firm Sunquest Information Systems have formalized their relationship. The two companies, which showed integration work at the 1998 RSNA meeting (
PNN
1/99), have wrapped up a deal that gives Tucson, AZ-based Sunquest the ability to sell the Amicas Web/Intranet Image Server. The deal will provide customers with a cohesive, Internet-based PACS offering by linking Watertown, MA-based Amicas product to Sunquests FlexiRad RIS. With the integration of the two products, users can access images from electronic patient records, according to the companies.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
